ancriviroc

Home
Ligands
ancriviroc

Ligand id: 804

Name: ancriviroc

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	3
Hydrogen bond donors	0
Rotatable bonds	7
Topological polar surface area	72.08
Molecular weight	556.2
XLogP	5.43
No. Lipinski's rules broken	1

Molecular properties generated using the CDK

Classification
Compound class	Synthetic organic

IUPAC Name
[4-[4-[(Z)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone

IUPAC Name

[4-[4-[(Z)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone

International Nonproprietary Names
INN number	INN
8459	ancriviroc

Synonyms
SCH 351125
SCH-351125
SCH-C

Synonyms

SCH 351125

SCH-351125

SCH-C

Database Links
BindingDB Ligand	50339956
CAS Registry No.	370893-06-4 (source: Scifinder)
ChEMBL Ligand	CHEMBL78535
PubChem CID	9574343
Search Google for chemical match using the InChIKey	ZGDKVKUWTCGYOA-URGPHPNLSA-N
Search Google for chemicals with the same backbone	ZGDKVKUWTCGYOA
Search PubMed clinical trials	ancriviroc
Search PubMed titles	ancriviroc
Search PubMed titles/abstracts	ancriviroc

Comments
Ancriviroc (SCH351125) is an orally available, small molecule antagonist of the C-C chemokine receptor type 5 (CCR5) expressed on T cells [4]. The compound was originally investigated as an anti-HIV therapeutic [4]. SCH351125-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results [6]. Other CCR5 antagonists (AZD5672 and maraviroc) have also proven ineffective in RA clinical trials [5]. There is some ambiguity in the literature and online databases as to the exact structure of ancriviroc. The structure shown here matches that in the PubChem entry linked to above, and as shown in [4], while other common representations of ancriviroc match CID 5479787.

Comments

Ancriviroc (SCH351125) is an orally available, small molecule antagonist of the C-C chemokine receptor type 5 (CCR5) expressed on T cells [4]. The compound was originally investigated as an anti-HIV therapeutic [4]. SCH351125-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results [6]. Other CCR5 antagonists (AZD5672 and maraviroc) have also proven ineffective in RA clinical trials [5].

There is some ambiguity in the literature and online databases as to the exact structure of ancriviroc. The structure shown here matches that in the PubChem entry linked to above, and as shown in [4], while other common representations of ancriviroc match CID 5479787.